Top Page
Challenger
(Sydney:CGF)
Challenger (CGF) vs. iShares MSCI Australia ETF (EWA)
Challenger Business Overview & Revenue Model
Challenger Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.20B | 750.50M | 3.28B | 2.23B | -414.30M | 3.03B |
| Gross Profit | 750.50M | 750.50M | 635.90M | 652.20M | 1.36B | 1.79B |
| EBITDA | 1.07B | 1.11B | 924.70M | 970.50M | 414.30M | 1.17B |
| Net Income | 192.30M | 192.30M | 129.90M | 287.50M | 253.70M | 592.30M |
Balance Sheet | ||||||
| Total Assets | 34.95B | 34.95B | 33.41B | 30.98B | 29.74B | 29.99B |
| Cash, Cash Equivalents and Short-Term Investments | 32.39B | 32.39B | 573.20M | 593.40M | 733.10M | 989.40M |
| Total Debt | 8.27B | 8.27B | 7.13B | 5.89B | 5.85B | 6.39B |
| Total Liabilities | 31.09B | 31.09B | 29.52B | 26.81B | 25.75B | 26.17B |
| Stockholders Equity | 3.86B | 3.86B | 3.88B | 4.16B | 3.99B | 3.83B |
Cash Flow | ||||||
| Free Cash Flow | 399.40M | 399.40M | 841.80M | 1.27B | 2.48B | 2.56B |
| Operating Cash Flow | 399.60M | 399.60M | 843.70M | 1.27B | 2.49B | 2.58B |
| Investing Cash Flow | -1.18B | -1.18B | -1.94B | -1.34B | -2.12B | -865.00M |
| Financing Cash Flow | 854.70M | 854.70M | 1.08B | -35.00M | -619.80M | -1.38B |
Challenger Technical Analysis
Challenger Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
64 Neutral | AU$6.13B | 52.47 | 67.81% | 1.45% | 28.29% | 39.39% | |
62 Neutral | AU$131.05M | 17.11 | 8.88% | ― | 21.79% | -23.00% | |
61 Neutral | AU$3.75B | 27.42 | 19.56% | 3.45% | 37.42% | 38.37% | |
60 Neutral | AU$6.26B | 32.46 | 4.84% | 3.10% | 11.78% | 47.53% | |
56 Neutral | AU$2.09B | 23.64 | 5.31% | ― | 16.78% | 22.86% | |
50 Neutral | €2.16B | -36.61 | -3.34% | 6.01% | 2.87% | 87.93% |
Challenger Corporate Events
Challenger Limited has notified the ASX that it has ceased to be a substantial holder in Telix Pharmaceuticals Ltd, formally lodging the required notice under the Corporations Act. The change indicates Challenger and its associated entities have reduced their holding in Telix below the substantial shareholder threshold, signaling a shift in their investment exposure to the biotech company and potentially altering Telix’s institutional shareholder base and governance dynamics.
The most recent analyst rating on (AU:CGF) stock is a Hold with a A$9.50 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
Challenger Limited has issued 179,017 unquoted performance rights under its employee incentive scheme, effective 16 January 2026. The grant of these performance rights, which will not be quoted on the ASX, underscores the company’s continued use of equity-based remuneration to align staff incentives with shareholder interests and support the retention and motivation of key employees.
The most recent analyst rating on (AU:CGF) stock is a Hold with a A$9.00 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
Challenger Limited has notified the market that 73,857 performance rights (ASX code: CGFAA) have lapsed as of 31 December 2025 after the conditions attached to those rights were not met or became incapable of being satisfied. The cessation of these securities reflects an adjustment to Challenger’s issued capital under its performance-based incentive arrangements, with no new shares issued as a result, and signals that certain performance hurdles tied to these rights were not achieved over the relevant period.
The most recent analyst rating on (AU:CGF) stock is a Buy with a A$10.25 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
Challenger Limited has disclosed that it, together with its controlled entities, holds or has derivative exposure to 50,197 ordinary shares in Challenger, representing 0.0073% of the company’s total issued capital, primarily via the Challenger Performance Plan Trust administered by CPU Share Plans Pty Limited. The notice, lodged under a Corporations Act exemption, details small net changes in this interest since October 2025 due to the forfeiture of shares and interests back to the trust from employee share plans, underscoring that current levels of treasury-like holdings tied to staff incentives remain immaterial in the context of Challenger’s overall share base but are being closely tracked for regulatory and governance transparency.
The most recent analyst rating on (AU:CGF) stock is a Buy with a A$10.25 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
Challenger Limited has announced its financial calendar for 2026, detailing key dates for half-year and full-year results, dividend announcements, and other significant events. This schedule provides stakeholders with a clear timeline for financial disclosures, which is crucial for investors and market analysts in planning and decision-making.
The most recent analyst rating on (AU:CGF) stock is a Buy with a A$10.25 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
Challenger Limited has announced a new distribution for its security, CAP NOTE 3-BBSW+3.60% PERP NON-CUM RED T-05-29, with a distribution amount of AUD 1.28. The payment is scheduled for February 25, 2026, following the record date of February 17, 2026. This discretionary distribution reflects Challenger’s ongoing commitment to providing returns to its investors, although it is contingent upon no payment conditions existing on the payment date.
The most recent analyst rating on (AU:CGF) stock is a Hold with a A$8.50 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
Challenger Limited has announced a new distribution for its Capital Notes 3, with a payment of AUD 1.46 scheduled for February 25, 2026. This discretionary distribution is subject to the absence of any payment conditions, reflecting Challenger’s ongoing commitment to providing returns to its stakeholders while maintaining flexibility in its financial operations.
The most recent analyst rating on (AU:CGF) stock is a Hold with a A$8.50 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
Challenger Limited announced that S&P Global Ratings has upgraded the credit ratings for both Challenger Life Company Limited and Challenger Limited, reflecting the company’s market leadership in the Australian annuities market and strong retirement savings trends. The upgrade highlights Challenger’s competitive advantage in risk management and capital adequacy, which supports its ability to navigate market and credit stress.
The most recent analyst rating on (AU:CGF) stock is a Hold with a A$8.50 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
Challenger Limited announced a change in the interests of its director, Nicolas Hamilton, who has acquired an additional 305,381 Hurdled Performance Share Rights as part of an annual remuneration review. This adjustment increases his total holdings to 1,680,858 Performance Rights and Restricted Shares under the Challenger Performance Plan, potentially impacting the company’s governance and aligning director incentives with company performance.
The most recent analyst rating on (AU:CGF) stock is a Hold with a A$8.50 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
Challenger Limited has announced the appointment of Damian Graham as the Group Chief Investment Officer, effective January 2026. This new role aims to integrate investment teams from Challenger Life and Funds Management, enhancing alignment of investment capabilities. Graham, with over 30 years of experience in investment management, will lead the unified investment team, leveraging his expertise in superannuation and retirement industries to drive investment excellence and support Challenger’s mission of providing financial security for better retirements.
The most recent analyst rating on (AU:CGF) stock is a Sell with a A$7.00 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.